Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price66.58 USD
Fair value55.30
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown66.58+0.0% to today
2026-08-22Read Accumulation81.21-18.0% to today
2026-07-02Read Markdown66.80-0.3% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
BridgeBio Pharma Inc holds its Markdown at $66.58. Consolidating, no directional conviction, held for 44 days.
As held on the ledger · 2026-09-21
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 44 days
Price at the screen
$66.58
Valuation
N/A trailing · 2,423.73 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.97
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
198.98%
Below 33%
Interest-bearing debt is 199.0% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
1.85%
Below 33%
Cash held in interest-bearing accounts and securities is 1.9% of assets, under the one-third limit.
Pass
Receivables
75.81%
Below 49%
Money owed to the company is 75.8% of assets, above the 49% limit.
Fail
Revenue purity
3.95%
Below 5%
Only 4.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
BridgeBio Pharma's business is in a permissible area, but its interest-bearing debt is about 199% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. The price runs 16.9% above the base estimate.
Third-party analyst targets: 21 covering, consensus Strong Buy. The average target sits +65% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Rare disease drug meets punishing price tag
Picture families waiting years for a pill that might slow a genetic heart condition. BridgeBio has delivered Attruby and revenue is leaping 67 percent, yet the business still burns cash at a 124 percent loss margin.
We pass. The shares trade at 81 dollars against our 56 dollar fair value, a forward multiple of 138 times earnings with a narrow moat and no margin of safety. Analyst targets sit higher, but the gap between price and reality is simply too wide.
Risk sits in binary trial outcomes and the constant need for fresh capital. One missed readout or fresh competitor can erase years of progress. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BBIO trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown · changed$66.58-18.0%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 18.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (23 analysts) rates it strong buy, with a mean price target of $102. Insiders have been net sellers over the past quarter.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (23 analysts) rates it strong buy, with a mean price target of $102.
2026-07-22Markdown$81.38+21.8%Entry 4
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 21.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (23 analysts) rates it strong buy, with a mean price target of $102.
2026-07-18Markdown$66.80+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 1% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 69%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (23 analysts) rates it strong buy, with a mean price target of $102.
2026-07-03Markdown$66.80+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markdown$66.80Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
